Citigroup increased its price target for Krystal Biotech to $416 from $386, citing strong Q2 revenue of $119.2 million from its approved product Vyjuvek and encouraging early clinical data for KB113, a treatment for basal cell carcinomas in Gorlin syndrome. Vyjuvek's success supports a solid financial position with $1.1 billion in cash and a 40% operating margin. The positive KB113 trial results, showing lesion shrinkage and mild side effects in three patients, will be presented at the PeDRA Annual Conference, indicating potential growth for Krystal Biotech's pipeline and stock value.
Krystal Biotech's recent strong Q2 revenue of $119.2 million and a robust $1.1 billion cash position provide important context. For readers following the health sector, here is Pluang's market snapshot as of Oct 16, 2026 00:41 WIB: out of 150 priced US health stocks, 137 rose and 12 fell. Notable movers include Moderna (MRNA) at USD 238.25 with a 5.28% gain and 83% buy order activity, Elanco Animal Health (ELAN) up 5.19% at USD 23.72, and Alumis Inc. (ALMS) rising 4.95% to USD 6.36 with 100% buy orders and a typical hold time of 0 days.
Bank7 Corp. reported Q3 2026 earnings of $1.06 per share, slightly beating analyst estimates, while revenue of $23.37 million fell short and declined year-over-year. Despite lower revenue and earnings compared to last year, the bank continues to grow...
Scotiabank increased its price target for Targa Resources to $319 from $314, indicating a potential 12.7% upside from the current share price of around $283. Targa Resources, a key player in the midstream energy sector, is recognized as a top momentu...
Ericsson reported better-than-expected Q3 earnings with EPS of $0.18 and revenue of $5.91 billion, driven by strong demand in its mobile network segment. The Networks division showed 9% organic growth and a gross margin above guidance, but overall op...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
Alice collaborated with Inflection AI and AI21 to demonstrate that NVIDIA Nemotron open models can be post-trained using real-world adversarial data to enhance AI safety and security without losing capability. Inflection AI improved conversational AI...
